首页> 外文OA文献 >Stepwise self-titration of oral glucose-lowering medication using a mobile telephone-based telehealth platform in type 2 diabetes: a feasibility trial in primary care.
【2h】

Stepwise self-titration of oral glucose-lowering medication using a mobile telephone-based telehealth platform in type 2 diabetes: a feasibility trial in primary care.

机译:使用基于移动电话的远程医疗平台对2型糖尿病患者进行口服降糖药物逐步自我滴定:在初级保健中的可行性试验。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Telehealth-supported clinical interventions may improve diabetes self-management. We explored the feasibility of stepwise self-titration of oral glucose-lowering medication guided by a mobile telephone-based telehealth platform for improving glycemic control in type 2 diabetes. METHODS: We recruited 14 type 2 diabetes patients to a one-year feasibility study with 1:1 randomization. Intervention group patients followed a stepwise treatment plan for titration of oral glucose-lowering medication with self-monitoring of glycemia using real-time graphical feedback on a mobile telephone and remote nurse monitoring using a Web-based tool. We carried out an interim analysis at 6 months. RESULTS: We screened 3476 type 2 diabetes patients; 94% of the ineligible did not meet the eligibility criteria for hemoglobin A1c (HbA1c) or current treatment. Mean (standard deviation) patient age at baseline was 58 (11) years, HbA1c was 65 (12) mmol/mol (8.1% [1.1%]), body mass index was 32.9 (6.4) kg/m2, median [interquartile range (IQR)] diabetes duration was 2.6 (0.6 to 4.7) years, and 10 (71%) were men. The median (IQR) change in HbA1c from baseline to six months was -10 (-21 to 3) mmol/mol (-0.9% [-1.9% to 0%]) in the intervention group and -5 (-13 to 6) mmol/mol (-0.5% [-1.2% to 0.6%]) in the control group. Six out of seven intervention group patients and four out of seven control group patients changed their oral glucose-lowering medication (p = .24). CONCLUSIONS: Self-titration of oral glucose-lowering medication in type 2 diabetes with self-monitoring and remote monitoring of glycemia is feasible, and further studies using adapted recruitment strategies are required to evaluate whether it improves clinical outcomes.
机译:背景:远程医疗支持的临床干预措施可能会改善糖尿病的自我管理。我们探索了在基于移动电话的远程医疗平台的指导下逐步自我滴定口服降糖药物的可行性,以改善2型糖尿病的血糖控制。方法:我们招募了14名2型糖尿病患者,以1:1随机分配进行了为期一年的可行性研究。干预组患者遵循分步治疗计划,通过使用移动电话上的实时图形反馈和使用基于Web的工具进行远程护士监测来对血糖降低进行自我监测的滴定降糖药物。我们在6个月时进行了中期分析。结果:我们筛选了3476例2型糖尿病患者。 94%的不符合资格不符合血红蛋白A1c(HbA1c)或当前治疗的资格标准。基线时患者平均年龄(标准差)为58(11)岁,HbA1c为65(12)mmol / mol(8.1%[1.1%]),体重指数为32.9(6.4)kg / m2,中位[四分位数间距] (IQR)]糖尿病持续时间为2.6(0.6至4.7)年,男性为10(71%)。从基线到六个月,HbA1c的中位数(IQR)变化在干预组中为-10(-21至3)mmol / mol(-0.9%[-1.9%至0%]),在-5(-13至6)对照组))/ mmol / mol(-0.5%[-1.2%至0.6%])。七名干预组患者中的六名和七名对照组患者中的四名更换了口服降糖药物(p = 0.24)。结论:通过自我监测和远程监测血糖来对2型糖尿病患者口服降糖药进行自我滴定是可行的,需要采用适应性招募策略进行进一步研究,以评估其是否改善临床疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号